110 related articles for article (PubMed ID: 24457427)
1. Mutational profiling in melanocytic tumors: multiple somatic mutations and clinical implications.
Richetta AG; Silvestri V; Giancristoforo S; Rizzolo P; D'Epiro S; Graziano V; Mattozzi C; Navazio AS; Falchetti M; Calvieri S; Ottini L
Oncology; 2014; 86(2):104-8. PubMed ID: 24457427
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
3. Massively parallel sequencing analysis of benign melanocytic naevi.
Lozada JR; Geyer FC; Selenica P; Brown D; Alemar B; Merghoub T; Berger MF; Busam KJ; Halpern AC; Weigelt B; Reis-Filho JS; Hollmann TJ
Histopathology; 2019 Jul; 75(1):29-38. PubMed ID: 30791119
[TBL] [Abstract][Full Text] [Related]
4. Mutational status of naevus-associated melanomas.
Shitara D; Tell-Martí G; Badenas C; Enokihara MM; Alós L; Larque AB; Michalany N; Puig-Butille JA; Carrera C; Malvehy J; Puig S; Bagatin E
Br J Dermatol; 2015 Sep; 173(3):671-80. PubMed ID: 25857817
[TBL] [Abstract][Full Text] [Related]
5. Clonal architectures and driver mutations in metastatic melanomas.
Ding L; Kim M; Kanchi KL; Dees ND; Lu C; Griffith M; Fenstermacher D; Sung H; Miller CA; Goetz B; Wendl MC; Griffith O; Cornelius LA; Linette GP; McMichael JF; Sondak VK; Fields RC; Ley TJ; Mulé JJ; Wilson RK; Weber JS
PLoS One; 2014; 9(11):e111153. PubMed ID: 25393105
[TBL] [Abstract][Full Text] [Related]
6. Genetic alterations in melanocytic tumors.
Takata M; Saida T
J Dermatol Sci; 2006 Jul; 43(1):1-10. PubMed ID: 16750612
[TBL] [Abstract][Full Text] [Related]
7. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
8. Mutation stability in primary and metastatic melanoma: what we know and what we don't.
Varada S; Mahalingam M
Histol Histopathol; 2015 Jul; 30(7):763-70. PubMed ID: 25585249
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
10. [Gene abnormalities in melanoma and signal transduction antagonists].
Takada M
Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754
[No Abstract] [Full Text] [Related]
11. Melanoma: What do all the mutations mean?
Davis EJ; Johnson DB; Sosman JA; Chandra S
Cancer; 2018 Sep; 124(17):3490-3499. PubMed ID: 29663336
[TBL] [Abstract][Full Text] [Related]
12. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences.
Dai B; Cai X; Kong YY; Yang F; Shen XX; Wang LW; Kong JC
Hum Pathol; 2013 Aug; 44(8):1472-8. PubMed ID: 23528861
[TBL] [Abstract][Full Text] [Related]
13. Frequencies of KIT and GNAQ mutations in acral melanoma.
Puntervoll HE; Molven A; Akslen LA
J Cutan Pathol; 2014 Nov; 41(11):893-4. PubMed ID: 25363280
[No Abstract] [Full Text] [Related]
14. Lack of hotspot mutations in BRAF, NRAS, and KIT genes in primary meningeal melanocytic tumors of intermediate grade.
Kim YJ; Müller CS; Bohle RM
Clin Neuropathol; 2016; 35(3):151-3. PubMed ID: 26784966
[No Abstract] [Full Text] [Related]
15. Somatic driver mutations in melanoma.
Reddy BY; Miller DM; Tsao H
Cancer; 2017 Jun; 123(S11):2104-2117. PubMed ID: 28543693
[TBL] [Abstract][Full Text] [Related]
16. KIT, NRAS, and BRAF mutations in nail apparatus melanoma.
Dika E; Altimari A; Patrizi A; Gruppioni E; Fiorentino M; Piraccini BM; Misciali C; Barisani A; Fanti PA
Pigment Cell Melanoma Res; 2013 Sep; 26(5):758-60. PubMed ID: 23782496
[No Abstract] [Full Text] [Related]
17. Cytogenetic and mutational analyses of melanocytic tumors.
Gerami P; Busam KJ
Dermatol Clin; 2012 Oct; 30(4):555-66, v. PubMed ID: 23021045
[TBL] [Abstract][Full Text] [Related]
18. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Arnault JP; Mateus C; Escudier B; Tomasic G; Wechsler J; Hollville E; Soria JC; Malka D; Sarasin A; Larcher M; André J; Kamsu-Kom N; Boussemart L; Lacroix L; Spatz A; Eggermont AM; Druillennec S; Vagner S; Eychène A; Dumaz N; Robert C
Clin Cancer Res; 2012 Jan; 18(1):263-72. PubMed ID: 22096025
[TBL] [Abstract][Full Text] [Related]
19. The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma.
Yarbrough WG
Laryngoscope; 2002 Dec; 112(12):2114-28. PubMed ID: 12461329
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A mutations in multiple primary melanomas.
Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]